IoC2-Guided Remifentanil Titration for Early Postoperative Pain After Laparoscopic Cholecystectomy
Effect of IoC2-guided Remifentanil Titration on Early Postoperative Pain After Elective Laparoscopic Cholecystectomy: a Single-centre, Patient- and Assessor-blinded, Randomized Superiority Trial
This is a single-centre, patient- and outcome-assessor-blinded, active-controlled, randomized superiority trial. The study will test whether remifentanil titration guided by the Index of Consciousness 2 (IoC2) displayed on the Angel-6000 monitor reduces early postoperative pain during the first 60 minutes after post-anaesthesia care unit (PACU) arrival compared with standardized remifentanil titration with IoC2 concealed, in adults undergoing elective laparoscopic cholecystectomy for benign gallbladder disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Duan
- Phone Number: 86 13810385311
- Email: dya01610@btch.edu.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 102218
- Recruiting
- Beijing Tsinghua Changgung Hospital
-
Contact:
- Yi Duan, MD
- Phone Number: +86-13810385311
- Email: dya01610@btch.edu.cn
-
Contact:
- Email: dya01610@btch.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years, of any sex
- American Society of Anesthesiologists (ASA) physical status I-III
- Elective standard three- or four-port laparoscopic cholecystectomy under general anaesthesia for benign gallbladder disease (gallstones, chronic cholecystitis, or gallbladder polyps)
- Planned total intravenous anaesthesia, with the surgeon expecting completion through a standard laparoscopic approach
- Ability to understand the 0-10 NRS and follow-up procedures and to complete assessments in Chinese
- Written informed consent
Exclusion Criteria:
- Emergency surgery; active acute cholecystitis, cholangitis, or acute pancreatitis; planned open, single-port, robotic, common-bile-duct exploration, or combined surgery; or expected postoperative mechanical ventilation
- Persistent preoperative moderate-to-severe pain (resting NRS ≥4) or daily opioid use for more than 7 days during the preceding 30 days
- Severe cognitive, psychiatric, language, hearing, or communication impairment that precludes reliable pain assessment
- Severe cardiac, pulmonary, hepatic, or renal dysfunction, or another condition that in the investigator's judgement precludes standardized anaesthesia
- Contraindication to propofol, remifentanil, rocuronium, acetaminophen, a non-steroidal anti-inflammatory drug, dexamethasone, local anaesthetic, or the planned rescue medication
- Pregnancy or breastfeeding
- Frontal skin injury, severe adhesive allergy, or another condition preventing electrode placement
- Participation within the previous 3 months in another interventional study that could affect the primary outcome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental group
IoC2-guided remifentanil titration |
IoC2 displayed on Angel-6000 monitor; target range 35-45; titration step 0.5 ng/mL effect-site concentration |
|
Active Comparator: Control Group
Standardized titration with IoC2 concealed |
Standardized titration with IoC2 concealed |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
NRS(0-10 numerical rating scale) score
Time Frame: 60 minutes
|
60 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 27031-0-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.